allergic rhinitis
Conditions
Sponsors
Beijing Shijitan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: 300 seasonal AR patients in a clinical trial on prevention and treatment of allergic rhinitis in Hohhot, Inner Mongolia in 2023. (1) Age 18-69 years old, male or female; (2) Have a typical history of seasonal allergic rhinitis, and the diagnostic criteria for seasonal AR refer to the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (revised edition 2022); ? Symptoms: paroxysmal sneezing, watery nose, nasal itching and nasal congestion and other symptoms appear 2 or more, every day Symptoms lasting or accumulated for more than 1h may be accompanied by eye symptoms such as tearing, eye itching and eye redness. ? Signs: common nasal mucosa pale, edema, nasal watery secretions; Allergen testing in the past or at visit: at least one allergen is positive for SPT and/or serum specific IgE; (3) In patients with pollen allergy, the symptoms were more than 4 weeks in the previous pollen dissemination season, and the average TNSS score of patients before treatment was =6. The average score of nasal congestion symptom was =2, and at least one of the three symptom scores of sneezing, runny nose and itchy nose was =2. (4) Voluntary subjects and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with perennial allergic rhinitis, severe deviation of nasal septum, sinusitis, and nasal polyps; (2) Patients with serious heart, liver, kidney and brain diseases; (3) pregnant and nursing women; (4) Patients with moderate-to-severe asthma who were clearly diagnosed during the pollen season; (5) tricyclic antidepressants, immunosuppressive/immunomodulatory agents, oral hormone drugs were taken 4 weeks before enrollment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The risk of seasonal AR patients after pollen concentration adjustment decreased compared to 2023; | — |
Secondary
| Measure | Time frame |
|---|---|
| symptom score-Four-point method;symptom score-VAS visual analog scale;symptom score-RQLQ Scale;Total drug score; | — |
Countries
China
Contacts
Public ContactWang Xueyan
Beijing Shijitan Hospital, Capital Medical University
Outcome results
None listed